Newsletter summary

Text of news flash

[China Biopharmaceutical innovative Drug Research Progress unveiled at the Annual meeting of the American Society of Clinical Oncology] China Biopharmaceutical Group announced recentlyCrashgamedownloadThe first class of innovative drugs developed by Ailotinib, Abergerstine α, Piampril and other innovative drug projects such as FS222, bemosubai, TQB3617, TQB3728 and TQB2930 will present 52 latest research results at the annual meeting of the American Society of Clinical Oncology in 2024. These research results cover the clinical and basic research of bone and soft tissue sarcoma, lung cancer, head and neck tumor, digestive system tumor, gynecological tumor, breast cancer, malignant tumor and so on. This series of research results show the innovation ability and R & D strength of Chinese biopharmaceutical in the field of biomedicine, and are expected to bring new treatment options for related diseases. At the same time, the progress in the research and development of these innovative drugs also reflects China's rapid development in the field of biomedicine and the improvement of its international competitiveness. At the annual meeting of the American Society of Clinical Oncology, China Biopharmaceuticals will show the latest progress in innovative drug research to the global oncology community in the form of display boards, oral reports and poster displays. The publication of these research results will help to promote the influence and voice of China's biopharmaceutical industry in the international biomedical field. In addition, China Biopharmaceuticals will continue to increase investment in research and development to promote the development and listing of more innovative drugs. In the future, the company will continue to strengthen cooperation with international scientific research institutions and enterprises, jointly promote scientific research innovation and technological progress in the field of biomedicine, and bring more treatment options and hopes for patients around the world. It is worth noting that the progress of this innovative drug research and development in China's biopharmaceutical industry has also brought inspiration and reference to other enterprises in China's biomedical industry. Under the background of fierce competition in the global biomedical industry, Chinese biomedical enterprises need to constantly strengthen their innovation ability and enhance their R & D strength in order to cope with the increasingly fierce market competition. Generally speaking, the progress made by China Biopharmaceutical in innovative drug research and development not only helps to promote the development of the company itself, but also has a positive impact on the overall development of China's biomedical industry. In the future, Chinese biomedical enterprises are expected to occupy a more important position in the global biomedical industry and make greater contributions to the health and well-being of patients around the world.